{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:12:07Z","timestamp":1789567927078,"version":"build-2803163510"},"reference-count":101,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Aggressive B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) accounts for \u224860% of NHL in children\/adolescents. In newly diagnosed Burkitt lymphoma and diffuse large B\u2010cell lymphoma, short intensive multiagent chemotherapy is associated with a five\u2010year event\u2010free survival of around 90%. Very few children\/adolescents with aggressive B\u2010NHL show a relapsed\/refractory (r\/r) disease. The outcome is poor, with cure rates &lt;30%, and there is no standard of care. Rituximab\u2010containing salvage regimens may provide a complete\/partial response in 60\u201370% of cases. However, long\u2010term survival is &lt;10% for non\u2010transplanted patients. Autologous or allogeneic haematopoietic stem cell transplant is, nowadays, the best option for responding patients, with survival rates around 50%. The benefit of autologous\n                    <jats:italic>versus<\/jats:italic>\n                    allogeneic HSCT is not clear. Numerous novel therapies for r\/r B\u2010NHL are currently being tested in adults, including next\u2010generation monoclonal antibodies, novel cellular therapy strategies and therapies directed against new targets. Some are under investigation also in children\/adolescents\n                    <jats:bold>,<\/jats:bold>\n                    with promising preliminary results.\n                  <\/jats:p>","DOI":"10.1111\/bjh.16461","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T05:05:41Z","timestamp":1583471141000},"page":"826-843","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Treatment of relapsed\/refractory paediatric aggressive B\u2010cell non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2138-4894","authenticated-orcid":false,"given":"Maria L.","family":"Moleti","sequence":"first","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine \u2018Sapienza\u2019 University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1354-3659","authenticated-orcid":false,"given":"Anna M.","family":"Testi","sequence":"additional","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine \u2018Sapienza\u2019 University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine \u2018Sapienza\u2019 University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.677534"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","unstructured":"Armand P. Rodig S. Melnichenko V. Thieblemont C. Bouabdallah K. Tumyan G. \u00d6zcan M. Portino S. Fogliatto L. Caballero M.D. Walewski J. Gulbas Z. Ribrag V. Christian B. Perini G.F. Salles G. Svoboda J. Zain J. Patel S. Chen P.H. Ligon A.H. Ouyang J. Neuberg D. Redd R. Chatterjee A. Balakumaran A. Orlowski R. Shipp M.&Zinzani P.L.(2019)Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B\u2010Cell Lymphoma. Journal of Clinical Oncology Oct 14:JCO1901389. [Epub ahead of print].","DOI":"10.1200\/JCO.19.01389"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02647.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20121"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13764"},{"issue":"1","key":"e_1_2_12_8_1","first-page":"67","article-title":"Blinatumomab significantly enhanced cytotoxicity and T\u2010cell cytokine secretion against Burkitt lymphoma (BL) and primary mediastinal B\u2010cell lymphoma (PMBL)","volume":"182","author":"Awasthi A.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15783"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14078"},{"key":"e_1_2_12_11_1","first-page":"48","article-title":"Phase 2 trial of obinutuzumab, a humanized glycoengineered monoclonal CD20 antibody, in combination with ifosfamide, carboplatin and etoposide for relapsed\/refractory mature B\u2010cell non\u2010Hodgkin lymphoma","volume":"182","author":"Barth M.J.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0265-z"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"e_1_2_12_14_1","first-page":"353","article-title":"Bone marrow transplantation in 46 pediatric patients with non\u2010Hodgkin\u2019s lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children","volume":"15","author":"Bureo E.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_12_15_1","first-page":"4124","article-title":"Results of inter\u2010B\u2010NHL ritux 2010 \u2010 phase II study of DA\u2010EPOCH\u2010R for children and adolescents with primary mediastinal large B\u2010cell lymphoma (PMLBL) on behalf of European Intergroup for Childhood Non Hodgkin\u2019s Lymphoma (EICNHL) and Children\u2019s Oncology Group (COG)","volume":"130","author":"Burke G.A.A.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.27_2629"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05735.x"},{"key":"e_1_2_12_18_1","first-page":"24","article-title":"Role of HST in children and adolescents with refractory or relapsed NHL","volume":"182","author":"Burkhardt B.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_19_1","first-page":"23","article-title":"The use of ifosfamide, carboplatin, and etoposide in children with solid tumors","volume":"22","author":"Cairo M.S.","year":"1995","journal-title":"Seminars in Oncology"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402402"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3369"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15491"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.016"},{"key":"e_1_2_12_25_1","first-page":"(1)","article-title":"Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in\u2010vitroproliferation and enhanced overall survival in a preclinical Burkitt lymphoma. (BL) model","volume":"8","author":"Chu Y.","year":"2018","journal-title":"Oncoimmunology"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15753"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1060"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14820"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-349662"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-778480"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15734"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7211"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21585"},{"key":"e_1_2_12_36_1","first-page":"23","article-title":"Safety and efficacy of myeloablative conditioning autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed\/refractory mature B\u2010cell Non Hodgkin lymphoma","volume":"182","author":"Gardenswartz A.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.4.661"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422709"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-791566"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24722"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14951"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.255"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13040"},{"key":"e_1_2_12_48_1","first-page":"11","article-title":"Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20 + mature B\u2010cell lymphoma","volume":"182","author":"Goldman S.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.021"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.07.002"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1330472"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07393.x"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.121434"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.047"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388470"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2390"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199903)32:3<225::AID-MPO12>3.0.CO;2-N"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802108870"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.2921"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1646"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15778"},{"key":"e_1_2_12_67_1","first-page":"465","article-title":"High\u2010dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non\u2010Hodgkin\u2019s lymphoma","volume":"8","author":"Loiseau H.A.","year":"1991","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5827"},{"key":"e_1_2_12_71_1","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","article-title":"Results of the randomized Intergroup trial Inter\u2010B\u2010NHL Ritux 2010 for children and adolescents with high\u2010risk B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) and mature acute leukemia (B\u2010AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen","volume":"34","author":"Minard\u2010Colin V.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22905"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1519810"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.59"},{"key":"e_1_2_12_75_1","first-page":"37","article-title":"Ibrutinib significantly inhibited bruton\u2019s tyrosine kinase (BTK) phosphorylation, in\u2010vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model","volume":"182","author":"Nayyar G.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26105"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.8.2003.2003"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14240"},{"key":"e_1_2_12_81_1","first-page":"3294","article-title":"Improved treatment results in childhood B\u2010cell neoplasms with tailored intensification of therapy: a report of the Berlin\u2010Frankfurt\u2010Munster Group Trial NHL\u2010BFM 90","volume":"94","author":"Reiter A.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27873"},{"key":"e_1_2_12_83_1","first-page":"23","article-title":"Early response data for pediatric patients with non\u2010Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T\u2010cells","volume":"182","author":"Rivers J.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.194"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802561"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13242"},{"key":"e_1_2_12_87_1","first-page":"577","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B\u2010cell lymphoma","volume":"130","author":"Schuster S.J.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.151"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601460"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841591"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741058"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.10.002"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1305983"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0169-2"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.28_2629"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383"},{"key":"e_1_2_12_102_1","first-page":"37","article-title":"Novel agents in development in children and adolescents with hematological malignancies within the EMA","volume":"182","author":"Zwaan C.M.","year":"2018","journal-title":"British Journal of Haematology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16461","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T13:04:41Z","timestamp":1693573481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/bjh.16461"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16461","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"2019-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}